Amgen (AMGN) Reports In-Line Q4 EPS, Offers FY23 Guidance

Amgen (NASDAQ: AMGN) reported Q4 EPS of $4.09, in-line with the analyst estimate of $4.09. Revenue for the quarter came in at $6.8 billion versus the consensus estimate of $6.74 billion.

GUIDANCE:

Amgen sees FY2023 EPS of $17.40-$18.60, versus the consensus of $18.33. Amgen sees FY2023 revenue of $26-27.2 billion, versus the consensus of $27.3 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Amgen (AMGN) PT Raised to $388 at Guggenheim
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c